glutathione-responsive prodrug

glutathione-responsive prodrug Frontiers Preparation and Characterization of a

Name: glutathione-responsive prodrug Frontiers Preparation and Characterization of a
Brand: meijijudolehavre.com
SKU: 75273862770
Price: 25.84 USD
Availability: InStock
Rating: 4.3276 (23 reviews)

Preparation and Characterization of a Glutathione Responsive Doxorubicin Prodrug Modified by 2 Nitrobenzenesulfonamide GroupIts Selective Cytotoxicity Toward Cells with Enhanced Glutathione Production Glutathionetriggered prodrugs: Design strategies, potential applications, and perspectives Zhao 2024 Medicinal Research Reviews Wiley Online Library Balancing Stability and Payload Release in Glutathione Responsive PROTAC Prodrugs Targeting Prostate Cancer JACS Au Activatable theranostic prodrug scaffold with tunable drug release rate for sequential photodynamic and chemotherapy Wang 2024 Smart Molecules Wiley Online Library A glutathione responsive sulfur dioxide polymer prodrug selectively induces ferroptosis in gastric cancer therapy Biomaterials Science (RSC Publishing) DOI:10.1039 D2BM00678B Synthesis of Glutathione Responsive Cyclomatrix Polyphosphazene for Multimodal Theranostic Nanodrug Delivery ACS Applied Polymer Materials

SKU: 75273862770 · From meijijudolehavre.com

4.3

USD25.84 USD46.84

Pay in 4 interest-free payments of $6.46 Learn more

Shipping Estimate
USA

USA

CAN

Ships within 48 hours · Estimated delivery Aug 7 - Aug 12

Description

Beyond Reconstitution: Storage and Handling of Reconstituted Peptides Once you've successfully managed how to reconstitute 60 mg tirzepatide, the journey isn't over

10.1007/s10533-018-0458-6 [DOI] [Google Scholar] Zhu XM, Hackl S, Thaker MN, Kalan L, Weber C, Urgast DS, Krupp EM, Brewer A, Vanner S, Szawiola A, Yim G, Feldmann J, Bechthold A, Wright GD, & Zechel DL (2015)

The extract is standardized to 98% trans-resveratrol

ITC analysis of a PL-containing synthetic peptide from DENND4C established direct binding to recombinant VPS29 with an affinity ( K d ) of 15.4 M, that was blocked by mutation of the PL motif or by the addition of a competing VPS29-binding macrocyclic peptide RT-D1 (Fig